Vascular Endothelial Growth Factor-Mimetic Peptide and Mitochondria-Targeted Antioxidant-Loaded Hydrogel System Improves Repair of Myocardial Infarction in Mice
Qingling Xu
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorXinhui Chen
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorShuwei Sun
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorChunyige Zhao
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorLinxin Shi
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorHan Cheng
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorCorresponding Author
Ying Liu
Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao, Shandong, China
Correspondence:
Ying Liu ([email protected])
Chunying Shi ([email protected])
Xiang Ao ([email protected])
Search for more papers by this authorCorresponding Author
Chunying Shi
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Correspondence:
Ying Liu ([email protected])
Chunying Shi ([email protected])
Xiang Ao ([email protected])
Search for more papers by this authorCorresponding Author
Xiang Ao
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Correspondence:
Ying Liu ([email protected])
Chunying Shi ([email protected])
Xiang Ao ([email protected])
Search for more papers by this authorQingling Xu
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorXinhui Chen
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorShuwei Sun
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorChunyige Zhao
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorLinxin Shi
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorHan Cheng
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Search for more papers by this authorCorresponding Author
Ying Liu
Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao, Shandong, China
Correspondence:
Ying Liu ([email protected])
Chunying Shi ([email protected])
Xiang Ao ([email protected])
Search for more papers by this authorCorresponding Author
Chunying Shi
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Correspondence:
Ying Liu ([email protected])
Chunying Shi ([email protected])
Xiang Ao ([email protected])
Search for more papers by this authorCorresponding Author
Xiang Ao
School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Correspondence:
Ying Liu ([email protected])
Chunying Shi ([email protected])
Xiang Ao ([email protected])
Search for more papers by this authorFunding: This work was supported by Natural Science Foundation of Shandong Province (ZR2023MC168 and ZR2023MH299).
Qingling Xu, Xinhui Chen and Shuwei Sun have contributed equally to this work and share first authorship.
ABSTRACT
Myocardial infarction (MI) is a pathological state characterized by persistent ischemia of the heart. Following MI, the structural and functional remodeling of the myocardium and vasculature involves oxidative stress and mitochondrial dysfunction, which exacerbate myocardial injury. Currently, there are limited effective treatments available to alleviate MI-induced damage. Vascular endothelial growth factor-mimetic (QK) peptides and mitochondria-targeted Szeto–Schiller (SS31) peptides have been extensively investigated for their therapeutic potential in various ischemic cardiomyopathies. However, traditional topical agents used in myocardial ischemia treatment suffer from limitations such as transient retention or undesirable diffusion of the drug. Consequently, a controlled drug delivery system capable of delivering QK and SS31 has gained significant attention for repair. In this study, we constructed self-assembled nanofibrous hydrogels incorporating QK and SS31 with customizable peptide amphiphilic (PA) molecules, resulting in PA1-QK and PA2-SS31 formulations. In vitro experiments demonstrated that both QK and SS31 effectively inhibited mitochondrial damage and apoptosis in a cellular hypoxia/reoxygenation (H/R) model. In vivo studies using a mouse MI model revealed that PA1-QK and PA2-SS31 significantly promoted vascular regeneration, attenuated mitochondrial dysfunction and apoptosis, and facilitated the recovery of cardiac structure and function. These results suggest that PA1-QK and PA2-SS31-loaded self-assembled nanofiber hydrogels represent an effective drug delivery system for promoting regenerative repair of myocardium and blood vessels following MI.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
All data required of the paper are included in the paper and/or the Supplementary For Peer Review Materials. The other related data may be requested from the authors.
References
- 1G. A. Roth, G. A. Mensah, C. O. Johnson, et al., “Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study,” Journal of the American College of Cardiology 76 (2020): 2982–3021.
- 2S. S. Virani, A. Alonso, E. J. Benjamin, et al., “Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association,” Circulation 141 (2020): e139–e596.
- 3Z. G. Zhao, H. Jilaihawi, Y. Feng, and M. Chen, “Transcatheter Aortic Valve Implantation in Bicuspid Anatomy,” Nature Reviews. Cardiology 12 (2015): 123–128.
- 4T. Y. Xiong, W. B. Ali, Y. Feng, et al., “Transcatheter Aortic Valve Implantation in Patients With Bicuspid Valve Morphology: A Roadmap Towards Standardization,” Nature Reviews. Cardiology 20 (2023): 52–67.
- 5G. A. Roth, C. Johnson, A. Abajobir, et al., “Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990–2015,” Journal of the American College of Cardiology 70 (2017): 1–25.
- 6D. Tomasoni, M. Adamo, C. M. Lombardi, and M. Metra, “Highlights in Heart Failure,” ESC Heart Failure 6 (2019): 1105–1127.
- 7H. Bulluck, D. M. Yellon, and D. J. Hausenloy, “Reducing Myocardial Infarct Size: Challenges and Future Opportunities,” Heart 102 (2016): 341–348.
- 8S. J. Geiseler and C. Morland, “The Janus Face of VEGF in Stroke,” International Journal of Molecular Sciences 19 (2018): 1362.
- 9C. Liu, Z. X. Yang, S. Q. Zhou, et al., “Overexpression of Vascular Endothelial Growth Factor Enhances the Neuroprotective Effects of Bone Marrow Mesenchymal Stem Cell Transplantation in Ischemic Stroke,” Neural Regeneration Research 18 (2023): 1286–1292.
- 10Y. Wu, J. Sun, Q. Lin, D. Wang, and J. Hai, “Sustained Release of Vascular Endothelial Growth Factor A and Basic Fibroblast Growth Factor From Nanofiber Membranes Reduces Oxygen/Glucose Deprivation-Induced Injury to Neurovascular Units,” Neural Regeneration Research 19 (2024): 887–894.
- 11J. Dornbusch, A. Zacharis, M. Meinhardt, et al., “Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients With Metastatic Renal Cell Carcinoma,” PLoS One 8 (2013): e76386.
- 12C. de Vries, J. A. Escobedo, H. Ueno, et al., “The Fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,” Science 255 (1992): 989–991.
- 13M. Feng, X. Liu, X. Hou, et al., “Specific Angiogenic Peptide Binding With Injectable Cardiac ECM Collagen Gel Promotes the Recovery of Myocardial Infarction in Rat,” Journal of Biomedical Materials Research. Part A 108 (2020): 1881–1889.
- 14R. Di Stasi, D. Diana, D. Capasso, et al., “VEGFR Recognition Interface of a Proangiogenic VEGF-Mimetic Peptide Determined In Vitro and in the Presence of Endothelial Cells by NMR Spectroscopy,” Chemistry 24 (2018): 11461–11466.
- 15B. Li, Y. Li, S. Chen, Y. Wang, and Y. Zheng, “VEGF Mimetic Peptide-Conjugated Nanoparticles for Magnetic Resonance Imaging and Therapy of Myocardial Infarction,” Journal of Controlled Release 360 (2023): 44–56.
- 16A. Pal, C. I. Smith, J. Palade, et al., “Poly(N-Isopropylacrylamide)-Based Dual-Crosslinking Biohybrid Injectable Hydrogels for Vascularization,” Acta Biomaterialia 107 (2020): 138–151.
- 17D. J. Hausenloy and D. M. Yellon, “Myocardial Ischemia-Reperfusion Injury: A Neglected Therapeutic Target,” Journal of Clinical Investigation 123 (2013): 92–100.
- 18G. Heusch, “Myocardial Ischaemia-Reperfusion Injury and Cardioprotection in Perspective,” Nature Reviews. Cardiology 17 (2020): 773–789.
- 19A. V. Birk, S. Liu, Y. Soong, et al., “The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting With Cardiolipin,” Journal of the American Society of Nephrology 24 (2013): 1250–1261.
- 20A. G. Nickel, A. von Hardenberg, M. Hohl, et al., “Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure,” Cell Metabolism 22 (2015): 472–484.
- 21M. Suo, Y. Qi, L. Liu, et al., “SS31 Alleviates Pressure Overload-Induced Heart Failure Caused by Sirt3-Mediated Mitochondrial Fusion,” Frontiers in Cardiovascular Medicine 9 (2022): 858594.
- 22Y. Liu, W. Yang, X. Sun, et al., “SS31 Ameliorates Sepsis-Induced Heart Injury by Inhibiting Oxidative Stress and Inflammation,” Inflammation 42 (2019): 2170–2180.
- 23F. Y. Lee, P. L. Shao, C. G. Wallace, et al., “Combined Therapy With SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats,” International Journal of Molecular Sciences 19 (2018): 2782.
- 24R. Li, Z. Lin, Q. Zhang, et al., “Injectable and In Situ-Formable Thiolated Chitosan-Coated Liposomal Hydrogels as Curcumin Carriers for Prevention of In Vivo Breast Cancer Recurrence,” ACS Applied Materials and Interfaces 12 (2020): 17936–17948.
- 25Q. Liu, J. Xie, R. Zhou, et al., “A Matrix Metalloproteinase-Responsive Hydrogel System Controls Angiogenic Peptide Release for Repair of Cerebral Ischemia/Reperfusion Injury,” Neural Regeneration Research 20 (2025): 503–517.
- 26W. Xu, Y. Wu, H. Lu, et al., “Injectable Hydrogel Encapsulated With VEGF-Mimetic Peptide-Loaded Nanoliposomes Promotes Peripheral Nerve Repair In Vivo,” Acta Biomaterialia 160 (2023): 225–238.
- 27N. Peyravian, P. B. Milan, M. M. Kebria, et al., “Designing and Synthesis of Injectable Hydrogel Based on Carboxymethyl Cellulose/Carboxymethyl Chitosan Containing QK Peptide for Femoral Head Osteonecrosis Healing,” International Journal of Biological Macromolecules 270 (2024): 132127.
- 28R. Li, C. Zhou, J. Chen, et al., “Synergistic Osteogenic and Angiogenic Effects of KP and QK Peptides Incorporated With an Injectable and Self-Healing Hydrogel for Efficient Bone Regeneration,” Bioactive Materials 18 (2022): 267–283.
- 29Z. Zheng, C. Lei, H. Liu, et al., “A ROS-Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial Infarction,” Advanced Healthcare Materials 11 (2022): e2200990.
- 30X. Zhang, Y. Sun, R. Yang, et al., “An Injectable Mitochondria-Targeted Nanodrug Loaded-Hydrogel for Restoring Mitochondrial Function and Hierarchically Attenuating Oxidative Stress to Reduce Myocardial Ischemia-Reperfusion Injury,” Biomaterials 287 (2022): 121656.
- 31J. Zhou, H. Zhang, M. S. Fareed, et al., “An Injectable Peptide Hydrogel Constructed of Natural Antimicrobial Peptide J-1 and ADP Shows Anti-Infection, Hemostasis, and Antiadhesion Efficacy,” ACS Nano 16 (2022): 7636–7650.
- 32H. Zhang, Z. Wu, J. Zhou, et al., “The Antimicrobial, Hemostatic, and Anti-Adhesion Effects of a Peptide Hydrogel Constructed by the All-d-Enantiomer of Antimicrobial Peptide Jelleine-1,” Advanced Healthcare Materials 12 (2023): e2301612.
- 33L. D. D'Andrea, G. Iaccarino, R. Fattorusso, et al., “Targeting Angiogenesis: Structural Characterization and Biological Properties of a De Novo Engineered VEGF Mimicking Peptide,” Proceedings of the National Academy of Sciences of the United States of America 102 (2005): 14215–14220.
- 34Z. Alvarez, A. N. Kolberg-Edelbrock, I. R. Sasselli, et al., “Bioactive Scaffolds With Enhanced Supramolecular Motion Promote Recovery From Spinal Cord Injury,” Science 374 (2021): 848–856.
- 35Z. Liu, H. Pan, Y. Zhang, et al., “Ginsenoside-Rg1 Attenuates Sepsis-Induced Cardiac Dysfunction by Modulating Mitochondrial Damage via the P2X7 Receptor-Mediated Akt/GSK-3beta Signaling Pathway,” Journal of Biochemical and Molecular Toxicology 36 (2022): e22885.
- 36Y. C. Zhao, L. W. Xu, S. Ding, et al., “Nuclear Receptor Retinoid-Related Orphan Receptor Alpha Deficiency Exacerbates High-Fat Diet-Induced Cardiac Dysfunction Despite Improving Metabolic Abnormality,” Biochimica et Biophysica Acta—Molecular Basis of Disease 1863 (2017): 1991–2000.
- 37Y. Chen, L. Zhang, W. X. Liu, and K. Wang, “VEGF and SEMA4D Have Synergistic Effects on the Promotion of Angiogenesis in Epithelial Ovarian Cancer,” Cellular and Molecular Biology Letters 23 (2018): 2.
- 38H. L. Sullivan, N. C. Gianneschi, and K. L. Christman, “Targeted Nanoscale Therapeutics for Myocardial Infarction,” Biomaterials Science 9 (2021): 1204–1216.
- 39A. Magadum, K. Kaur, and L. Zangi, “mRNA-Based Protein Replacement Therapy for the Heart,” Molecular Therapy 27 (2019): 785–793.
- 40R. S. Apte, D. S. Chen, and N. Ferrara, “VEGF in Signaling and Disease: Beyond Discovery and Development,” Cell 176 (2019): 1248–1264.
- 41L. De Rosa, R. Di Stasi, and L. D. D'Andrea, “Pro-Angiogenic Peptides in Biomedicine,” Archives of Biochemistry and Biophysics 660 (2018): 72–86.
- 42A. H. Van Hove, M. J. Beltejar, and D. S. Benoit, “Development and In Vitro Assessment of Enzymatically-Responsive Poly(Ethylene Glycol) Hydrogels for the Delivery of Therapeutic Peptides,” Biomaterials 35 (2014): 9719–9730.
- 43J. Su, S. C. Satchell, J. A. Wertheim, and R. N. Shah, “Poly(Ethylene Glycol)-Crosslinked Gelatin Hydrogel Substrates With Conjugated Bioactive Peptides Influence Endothelial Cell Behavior,” Biomaterials 201 (2019): 99–112.
- 44D. Diana, B. Ziaco, G. Colombo, et al., “Structural Determinants of the Unusual Helix Stability of a De Novo Engineered Vascular Endothelial Growth Factor (VEGF) Mimicking Peptide,” Chemistry 14 (2008): 4164–4166.
- 45F. Finetti, A. Basile, D. Capasso, et al., “Functional and Pharmacological Characterization of a VEGF Mimetic Peptide on Reparative Angiogenesis,” Biochemical Pharmacology 84 (2012): 303–311.
- 46M. Bonora, M. R. Wieckowski, D. A. Sinclair, G. Kroemer, P. Pinton, and L. Galluzzi, “Targeting Mitochondria for Cardiovascular Disorders: Therapeutic Potential and Obstacles,” Nature Reviews. Cardiology 16 (2019): 33–55.
- 47O. S. Kornfeld, S. Hwang, M. H. Disatnik, C. H. Chen, N. Qvit, and D. Mochly-Rosen, “Mitochondrial Reactive Oxygen Species at the Heart of the Matter: New Therapeutic Approaches for Cardiovascular Diseases,” Circulation Research 116 (2015): 1783–1799.
- 48D. F. Dai, T. Chen, H. Szeto, et al., “Mitochondrial Targeted Antioxidant Peptide Ameliorates Hypertensive Cardiomyopathy,” Journal of the American College of Cardiology 58 (2011): 73–82.
- 49H. H. Szeto, “First-In-Class Cardiolipin-Protective Compound as a Therapeutic Agent to Restore Mitochondrial Bioenergetics,” British Journal of Pharmacology 171 (2014): 2029–2050.
- 50Y. A. Chiao, H. Zhang, M. Sweetwyne, et al., “Late-Life Restoration of Mitochondrial Function Reverses Cardiac Dysfunction in Old Mice,” eLife 9 (2020): e55513.
- 51S. Frantz, J. Bauersachs, and G. Ertl, “Post-Infarct Remodelling: Contribution of Wound Healing and Inflammation,” Cardiovascular Research 81 (2009): 474–481.
- 52H. I. Lu, F. Y. Lee, C. G. Wallace, et al., “SS31 Therapy Effectively Protects the Heart Against Transverse Aortic Constriction-Induced Hypertrophic Cardiomyopathy Damage,” American Journal of Translational Research 9 (2017): 5220–5237.
- 53X. Du, Q. Zeng, Y. Luo, et al., “Application Research of Novel Peptide Mitochondrial-Targeted Antioxidant SS-31 in Mitigating Mitochondrial Dysfunction,” Mitochondrion 75 (2024): 101846.
- 54W. Reid Thompson, B. Hornby, R. Manuel, et al., “A Phase 2/3 Randomized Clinical Trial Followed by an Open-Label Extension to Evaluate the Effectiveness of Elamipretide in Barth Syndrome, a Genetic Disorder of Mitochondrial Cardiolipin Metabolism,” Genetics in Medicine 23 (2021): 471–478.